Lauren Santye, Assistant Editor

Only half of locally advanced rectal cancer patients receive standard therapy, which is affected by demographic factors.

Study finds medication reconciliation reduces error incidence in cancer patients undergoing chemotherapy.

Modified common flu adenovirus helps treat drug resistant cancers.

Study may lead to the development of treatments for disorders with damaged myelin sheath.

Individualized treatment for lymphoma may lead to a new standard of care.

Numerous factors besides adherence influence effective medication management.

Alecensa shows superiority to crizotinib in advanced or recurrent, ALK-positive non-small cell lung cancer.

Alecensa found superior to crizotinib in advanced or recurrent, ALK-positive non-small cell lung cancer.

Increased gut bacteria linked to inflammation among children with multiple sclerosis.

Douglas Samojedny, RPh, director of Pharmacy Operations at Pharmacy Advantage, discusses initiatives to optimize medication adherence.

Mutations that affect protein levels impact tumor growth.

Top news of the day from across the healthcare landscape.

Atezolizumab (Tecentriq) approved for locally advanced or metastatic urothelial carcinoma.

Atezolizumab (Tecentriq) approved for locally advanced or metastatic urothelial carcinoma.

Pharmacists can have a positive influence on medication adherence and several other factors in type 2 diabetes.

Uneven distribution of the signaling protein c-Myc could aid the development of cancer vaccines.

The United States reduced cancer mortality by 26% overall, falling short of the 50% reduction goal set by the American Cancer Society.

Nintedanib found to slow disease progression and slow lung function decline.

Nondiscrimination in Health Programs and Activities final rule addresses discrimination and seeks to improve language barriers.

Top news of the day from across the health care landscape.

Agreement will modify the costs of the cholesterol-lowering drugs Repatha and Praluent based on efficacy in patients.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Contracts will modify the costs of the cholesterol-lowering drugs Repatha and Praluent based on efficacy in patients.

Imbruvica approved for use in patients with chronic lymphocytic leukemia and small lymphocytic lymphoma.

Slow-binding inhibitors of cholinesterases could produce treatments for Alzheimer's disease, myasthenia, and neuroprotection.

Children found to greatly benefit from gene therapy for Leber congenital amaurosis.

Top news of the day from across the health care landscape.

Personal preference influence pharmacist recommendations for a host of conditions.

Dendritic cell-based therapy shows promise treating diabetic peripheral neuropathy and ulcerations in the cornea and skin.

Top news of the day from across the health care landscape.